MiRNA Deregulation Distinguishes Anaplastic Thyroid Carcinoma (ATC) and Supports Upregulation of Oncogene Expression

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Dec 10

PMID 34885022

Citations 6

Authors

Danny Misiak

Marcus Bauer

Jana Lange

Jacob Haase

Juliane Braun

Kerstin Lorenz

Claudia Wickenhauser

Stefan Huttelmaier

Affiliations

Soon will be listed here.

Abstract

Anaplastic thyroid carcinoma (ATC) is the most fatal and rapidly evolving endocrine malignancy invading the head and neck region and accounts for up to 50% of thyroid cancer-associated deaths. Deregulation of the microRNA (miRNA) expression promotes thyroid carcinoma progression by modulating the reorganization of the ATC transcriptome. Here, we applied comparative miRNA-mRNA sequencing on a cohort of 28 thyroid carcinomas to unravel the association of deregulated miRNA and mRNA expression. This identified 85 miRNAs significantly deregulated in ATC. By establishing a new analysis pipeline, we unraveled 85 prime miRNA-mRNA interactions supporting the downregulation of candidate tumor suppressors and the upregulation of bona fide oncogenes such as survivin (BIRC5) in ATC. This miRNA-dependent reprogramming of the ATC transcriptome provided an mRNA signature comprising 65 genes sharply distinguishing ATC from other thyroid carcinomas. The validation of the deregulated protein expression in an independent thyroid carcinoma cohort demonstrates that miRNA-dependent oncogenes comprised in this signature, the transferrin receptor TFRC (CD71) and the E3-ubiquitin ligase DTL, are sharply upregulated in ATC. This upregulation is sufficient to distinguish ATC even from poorly differentiated thyroid carcinomas (PDTC). In sum, these findings provide new diagnostic tools and a robust resource to explore the key miRNA-mRNA regulation underlying the progression of thyroid carcinoma.

Citing Articles

New Horizons of Biomarkers in Metastatic Thyroid Cancer.

Cendra A, Pekarek L, Pedrejon B, Bernier L, Cervantes E, Cendra C J Cancer. 2025; 16(1):241-264.

PMID: 39744583 PMC: 11660124. DOI: 10.7150/jca.101395.

MicroRNA regulator gene mutations in thyroid follicular nodular disease and thyroid cancer: does it all come down to timing?.

Condello V, Juhlin C Eur Thyroid J. 2024; 13(6).

PMID: 39601261 PMC: 11737542. DOI: 10.1530/ETJ-24-0298.

Ubiquitin-modifying enzymes in thyroid cancer：Mechanisms and functions.

Xiong X, Huang B, Gan Z, Liu W, Xie Y, Zhong J Heliyon. 2024; 10(13):e34032.

PMID: 39091932 PMC: 11292542. DOI: 10.1016/j.heliyon.2024.e34032.

Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma.

Yang F, Niu X, Zhou M, Li W Sci Rep. 2024; 14(1):14436.

PMID: 38910181 PMC: 11194273. DOI: 10.1038/s41598-024-65194-y.

The Role of miRNAs to Detect Progression, Stratify, and Predict Relevant Clinical Outcomes in Bladder Cancer.

Torres-Bustamante M, Vazquez-Urrutia J, Solorzano-Ibarra F, Ortiz-Lazareno P Int J Mol Sci. 2024; 25(4).

PMID: 38396855 PMC: 10889402. DOI: 10.3390/ijms25042178.

References

Cui H, Wang Q, Lei Z, Feng M, Zhao Z, Wang Y . DTL promotes cancer progression by PDCD4 ubiquitin-dependent degradation. J Exp Clin Cancer Res. 2019; 38(1):350. PMC: 6693180. DOI: 10.1186/s13046-019-1358-x. View

Frezzetti D, Reale C, Cali G, Nitsch L, Fagman H, Nilsson O . The microRNA-processing enzyme Dicer is essential for thyroid function. PLoS One. 2011; 6(11):e27648. PMC: 3221669. DOI: 10.1371/journal.pone.0027648. View

Testa U, Pelosi E, Castelli G, Labbaye C . miR-146 and miR-155: Two Key Modulators of Immune Response and Tumor Development. Noncoding RNA. 2018; 3(3). PMC: 5831915. DOI: 10.3390/ncrna3030022. View

Bell J, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M . Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?. Cell Mol Life Sci. 2012; 70(15):2657-75. PMC: 3708292. DOI: 10.1007/s00018-012-1186-z. View

Viola D, Valerio L, Molinaro E, Agate L, Bottici V, Biagini A . Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016; 23(4):R185-205. DOI: 10.1530/ERC-15-0555. View

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A . Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007; 26(54):7590-5. DOI: 10.1038/sj.onc.1210564. View

Busch B, Bley N, Muller S, Glass M, Misiak D, Lederer M . The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family. Nucleic Acids Res. 2016; 44(8):3845-64. PMC: 4856984. DOI: 10.1093/nar/gkw099. View

Elcheva I, Goswami S, Noubissi F, Spiegelman V . CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. Mol Cell. 2009; 35(2):240-6. PMC: 2742352. DOI: 10.1016/j.molcel.2009.06.007. View

Ohmura S, Marchetto A, Orth M, Li J, Jabar S, Ranft A . Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021; 20(1):97. PMC: 8314608. DOI: 10.1186/s12943-021-01393-9. View

10.

Bavelloni A, Ramazzotti G, Poli A, Piazzi M, Focaccia E, Blalock W . MiRNA-210: A Current Overview. Anticancer Res. 2017; 37(12):6511-6521. DOI: 10.21873/anticanres.12107. View

11.

Pishkari S, Paryan M, Hashemi M, Baldini E, Mohammadi-Yeganeh S . The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J Endocrinol Invest. 2017; 41(3):269-283. DOI: 10.1007/s40618-017-0735-6. View

12.

Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P . Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res. 2018; 8(6):916-931. PMC: 6048407. View

13.

Muller S, Bley N, Glass M, Busch B, Rousseau V, Misiak D . IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 2018; 46(12):6285-6303. PMC: 6158595. DOI: 10.1093/nar/gky229. View

14.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

15.

Haase D, Meister M, Muley T, Hess J, Teurich S, Schnabel P . FRMD3, a novel putative tumour suppressor in NSCLC. Oncogene. 2007; 26(30):4464-8. DOI: 10.1038/sj.onc.1210225. View

16.

Liao Y, Smyth G, Shi W . featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2013; 30(7):923-30. DOI: 10.1093/bioinformatics/btt656. View

17.

Tiedje V, Stuschke M, Weber F, Dralle H, Moss L, Fuhrer D . Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer. 2018; 25(3):R153-R161. DOI: 10.1530/ERC-17-0435. View

18.

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

19.

Haase J, Misiak D, Bauer M, Pazaitis N, Braun J, Potschke R . IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis. Mod Pathol. 2020; 34(1):32-41. PMC: 7806508. DOI: 10.1038/s41379-020-0630-0. View

20.

Braun J, Hoang-Vu C, Dralle H, Huttelmaier S . Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010; 29(29):4237-44. DOI: 10.1038/onc.2010.169. View